| Hospice Of New York, Llc 45-18 Court Square - Suite 500, Long Island City, NY, 11101 | |
| (718) 472-1999 |
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| Name | Hospice Of New York, Llc |
|---|---|
| Location | 45-18 Court Square - Suite 500, Long Island City, New York |
| Hospice ID | 331560 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 590 |
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| NPI Number | 1013001197 |
| Organization Name | Hospice Of New York, Llc |
| Address | 4518 Court Sq Ste 500 Long Island City, New York, 11101 |
| Phone Number | (718)472-1999 |
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.9 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 93.8 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 93.3 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 96.5 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 94.3 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.8 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 98.9 | 93.3 |
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| Counselors | 6 |
| Licensed Practical or Vocational Nurses | 4.5 |
| Medical Social Workers | 17.95 |
| Physicians | 5.31 |
| Registered Nurses | 49.88 |
| Other Personnel | 27.05 |
| Total Employees | 110.69 |
|---|
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| Others | 96 |
| Total Volunteers | 96 |
|---|
News Archive
Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
Three Limits of Human Performance debates will take place around the country as part of the etb's year-long Engineering in the Olympics campaign showcasing the sector's contribution to the Olympic experience.
› Verified 4 days ago
| Hospice Of New York, Llc Location: 45-18 Court Square - Suite 500, Long Island City, New York, 11101 Phone: (718) 472-1999 |